Commentary: Dying to Live – Why Is Health Care So Valuable in the Face of Death?
Tomas Philipson’s latest Forbes.com Op-Ed examines end of life care, and why health care is so valuable in the face of death.
Commentary: Big Data Analytics: The Next Evolution in Drug Development
Precision’s Deb Phippard, PhD, and Jared Kohler, PhD, address the potential of Big Data, analytics, and technology to increase efficiency and decrease costs in the drug development process in a guest column for Bioprocess Online. Read the full article here:
Commentary: The California Child Vaccination Mandates and the Everlasting Cycle of Infectious Diseases
Precision’s Tomas Philipson’s latest Forbes.com Op-Ed examines California’s recently enacted vaccination mandate, and the application of economic epidemiology.
Precision for Value Adds Prominent Health Economist Dr. Christopher Blanchette to its Expanding HEOR Team
NEW YORK, July 8, 2015 – Precision for Value (www.precisionforvalue.com), a Precision for Medicine Company which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the further expansion of its Health Economics and Outcomes Research (HEOR) team to meet growing customer demand. Christopher Blanchette, PhD, was appointed Vice President, Health Economics.
Precision’s Goldman Elected to ISPOR Board of Directors
Precision’s Dana Goldman has been elected to ISPOR’s Board of Directors, effective July 1st, 2015. The Board of Directors are elected by ISPOR members – over 9,500 global members were given the opportunity to vote for nominated candidates.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the world’s largest professional organization focused on pharmacoeconomics and outcomes research. Its total membership exceeds 16,500 from 120 countries worldwide.